PubMed

A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.

Viberti G, Lachin J, Holman R, Zinman B, Haffner S, Kravitz B, Heise MA, Jones NP, O'Neill MC, Freed MI, Kahn SE, Herman WH; for the ADOPT Study Group.

Diabet Med. 2006 Dec;23(12):1289-94.PMID: 17116177 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.

Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, Porter LE.

J Hypertens. 2006 Oct;24(10):2047-55.PMID: 16957566 [PubMed - indexed for MEDLINE]Related articles

Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.

Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, Herman WH, Holman RR, Jones NP, Lachin JM, Viberti GC; ADOPT Study Group.

Diabetes. 2006 Aug;55(8):2357-64.PMID: 16873701 [PubMed - indexed for MEDLINE]Related articlesFree article

Improving metabolic control leads to better working memory in adults with type 2 diabetes.

Ryan CM, Freed MI, Rood JA, Cobitz AR, Waterhouse BR, Strachan MW.

Diabetes Care. 2006 Feb;29(2):345-51.PMID: 16443885 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.

Rosenstock J, Goldstein BJ, Vinik AI, O'neill MC, Porter LE, Heise MA, Kravitz B, Dirani RG, Freed MI; RESULT Study Group.

Diabetes Obes Metab. 2006 Jan;8(1):49-57.PMID: 16367882 [PubMed - indexed for MEDLINE]Related articles

Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study.

Herman WH, Dirani RG, Horblyuk R, O'Neill MC, Kravitz B, Heise MA, Bakst A, Freed MI; RESULT Study Group.

Am J Manag Care. 2005 Apr;11(4):273-8.PMID: 15839187 [PubMed - indexed for MEDLINE]Related articlesFree article

Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes.

Smith SA, Porter LE, Biswas N, Freed MI.

J Clin Endocrinol Metab. 2004 Dec;89(12):6048-53.PMID: 15579757 [PubMed - indexed for MEDLINE]Related articlesFree article

Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe.

Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI; ADOPT Study Group.

Diabetes. 2004 Dec;53(12):3193-200.PMID: 15561950 [PubMed - indexed for MEDLINE]Related articlesFree article

Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency.

Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, Freed MI.

J Clin Pharmacol. 2003 Mar;43(3):252-9.PMID: 12638393 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone reduces urinary albumin excretion in type II diabetes.

Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI.

J Hum Hypertens. 2003 Jan;17(1):7-12.PMID: 12571611 [PubMed - indexed for MEDLINE]Related articles

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.

Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, Cohen BR, Brunzell JD; Rosiglitazone Study 108 investigators.

Am J Cardiol. 2002 Nov 1;90(9):947-52.PMID: 12398960 [PubMed - indexed for MEDLINE]Related articles

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.

Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, Freed MI.

Diabetes Care. 2002 Oct;25(10):1737-43.PMID: 12351470 [PubMed - indexed for MEDLINE]Related articlesFree article

Pharmacokinetics of rosiglitazone in patients with end-stage renal disease.

Thompson-Culkin K, Zussman B, Miller AK, Freed MI.

J Int Med Res. 2002 Jul-Aug;30(4):391-9.PMID: 12235921 [PubMed - indexed for MEDLINE]Related articles

The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.

Miller AK, DiCicco RA, Freed MI.

Clin Ther. 2002 Jul;24(7):1062-71.PMID: 12182252 [PubMed - indexed for MEDLINE]Related articles

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.

Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI.

Circulation. 2002 Aug 6;106(6):679-84.PMID: 12163427 [PubMed - indexed for MEDLINE]Related articlesFree article

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.

Lebovitz HE, Kreider M, Freed MI.

Diabetes Care. 2002 May;25(5):815-21.PMID: 11978674 [PubMed - indexed for MEDLINE]Related articlesFree article

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J; Rosiglitazone Clinical Trials Study Group.

Diabetes Care. 2001 Jul;24(7):1226-32.PMID: 11423507 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of acarbose on the pharmacokinetics of rosiglitazone.

Miller AK, Inglis AM, Culkin KT, Jorkasky DK, Freed MI.

Eur J Clin Pharmacol. 2001 May;57(2):105-9.PMID: 11417440 [PubMed - indexed for MEDLINE]Related articles

Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers.

Inglis AM, Miller AK, Culkin KT, Finnerty D, Patterson SD, Jorkasky DK, Freed MI.

J Clin Pharmacol. 2001 Jun;41(6):683-90.PMID: 11402638 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone monotherapy is effective in patients with type 2 diabetes.

Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI; Rosiglitazone Clinical Trials Study Group.

J Clin Endocrinol Metab. 2001 Jan;86(1):280-8. Erratum in: J Clin Endocrinol Metab 2001 Apr;86(4):1659. J Clin Endocrinol Metab. 2002 Feb;2(1):iv.. PMID: 11232013 [PubMed - indexed for MEDLINE]Related articlesFree article

Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin.

Di Cicco RA, Miller AK, Patterson S, Freed MI.

J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1516-21.PMID: 11185675 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone does not alter the pharmacokinetics of metformin.

Di Cicco RA, Allen A, Carr A, Fowles S, Jorkasky DK, Freed MI.

J Clin Pharmacol. 2000 Nov;40(11):1280-5.PMID: 11075314 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI.

Diabetologia. 2000 Mar;43(3):278-84.PMID: 10768088 [PubMed - indexed for MEDLINE]Related articles

Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism.

Wang A, Holcslaw T, Bashore TM, Freed MI, Miller D, Rudnick MR, Szerlip H, Thames MD, Davidson CJ, Shusterman N, Schwab SJ.

Kidney Int. 2000 Apr;57(4):1675-80.PMID: 10760103 [PubMed - indexed for MEDLINE]Related articlesFree article

Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics.

Harris RZ, Inglis AM, Miller AK, Thompson KA, Finnerty D, Patterson S, Jorkasky DK, Freed MI.

J Clin Pharmacol. 1999 Nov;39(11):1189-94.PMID: 10579151 [PubMed - indexed for MEDLINE]Related articles

Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular tone.

Freed MI, Wilson DE, Thompson KA, Harris RZ, Ilson BE, Jorkasky DK.

Clin Pharmacol Ther. 1999 May;65(5):473-82.PMID: 10340912 [PubMed - indexed for MEDLINE]Related articles

Systemic exposure to rosiglitazone is unaltered by food.

Freed MI, Allen A, Jorkasky DK, DiCicco RA.

Eur J Clin Pharmacol. 1999 Mar;55(1):53-6.PMID: 10206085 [PubMed - indexed for MEDLINE]Related articles

A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men.

Ilson BE, Boike SC, Martin DE, Freed MI, Zariffa N, Jorkasky DK.

Clin Pharmacol Ther. 1998 Apr;63(4):471-81.PMID: 9585802 [PubMed - indexed for MEDLINE]Related articles

SK&F107647: a synthetic hematoregulatory peptide in patients with solid tumor malignancies: a phase I trial.

Nemunaitis J, Martin DE, Willis DL, Freed MI, Levitt B, Richards DA, Cox JV, Kimmel GT, Hyman WJ, Jorkasky DK, Brocks DR.

Am J Clin Oncol. 1998 Apr;21(2):189-94. Erratum in: Am J Clin Oncol 1998 Dec;21(6):542. PMID: 9537210 [PubMed - indexed for MEDLINE]Related articles

Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus.

Martin DE, DeCherney GS, Ilson BE, Jones BA, Boike SC, Freed MI, Jorkasky DK.

J Clin Pharmacol. 1997 Feb;37(2):155-9.PMID: 9055142 [PubMed - indexed for MEDLINE]Related articles

Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients.

Brocks DR, Freed MI, Martin DE, Sellers TS, Mehdi N, Citerone DR, Boppana V, Levitt B, Davies BE, Nemunaitis J, Jorkasky DK.

Pharm Res. 1996 May;13(5):794-7.PMID: 8860439 [PubMed - indexed for MEDLINE]Related articles

Pharmacokinetics of famciclovir in subjects with chronic hepatic disease.

Boike SC, Pue M, Audet PR, Freed MI, Fairless A, Ilson BE, Zariffa N, Jorkasky DK.

J Clin Pharmacol. 1994 Dec;34(12):1199-207.PMID: 7738216 [PubMed - indexed for MEDLINE]Related articles

Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers.

Freed MI, Audet PR, Zariffa N, Krishna GG, Ilson BE, Everitt DE, Brown LE, Rizzo SM, Nichols AI, Jorkasky DK.

J Clin Pharmacol. 1994 Nov;34(11):1098-108.PMID: 7876402 [PubMed - indexed for MEDLINE]Related articles

Effect of acetylsalicylic acid on inhibition of ex vivo platelet aggregation and secretion by SKF 107260, a novel GPIIb/IIIa receptor antagonist.

Freed MI, Boike S, Zariffa N, Jorkasky DK.

Thromb Haemost. 1994 Oct;72(4):622-6.PMID: 7878642 [PubMed - indexed for MEDLINE]Related articles

Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment.

Boike SC, Pue MA, Freed MI, Audet PR, Fairless A, Ilson BE, Zariffa N, Jorkasky DK.

Clin Pharmacol Ther. 1994 Apr;55(4):418-26.PMID: 8162668 [PubMed - indexed for MEDLINE]Related articles

Effects of chronic metabolic acidosis on Na(+)-H+ exchangers in LLC-PK1 renal epithelial cells.

Igarashi P, Freed MI, Ganz MB, Reilly RF.

Am J Physiol. 1992 Jul;263(1 Pt 2):F83-8.PMID: 1322057 [PubMed - indexed for MEDLINE]Related articles

Effects of calcium channel blockers on potassium homeostasis.

Freed MI, Rastegar A, Bia MJ.

Yale J Biol Med. 1991 Mar-Apr;64(2):177-86. Review.PMID: 1750228 [PubMed - indexed for MEDLINE]Related articlesFree article

Aesthetic problems in chemical peeling.

Goldman PM, Freed MI.

J Dermatol Surg Oncol. 1989 Sep;15(9):1020-4.PMID: 2778182 [PubMed - indexed for MEDLINE]Related articles

Stoichiometry of large T antigen and pp53 in complexes isolated from simian virus 40-transformed rat cells.

Freed MI, Lubin I, Simmons DT.

J Virol. 1983 Jun;46(3):1061-5.PMID: 6304337 [PubMed - indexed for MEDLINE]Related articlesFree article